Pan-PI3K inhibitors such as copanlisib exhibit broad-spectrum adverse events (AEs), including hyperglycemia (5% grade ≥ 3), leukopenia, and infection-related complications such as pneumonia (8% incidence), likely attributable to ubiquitous pathway involvement in metabolic and immune homeostasis [48]. Here, PIK3CA is linked to pneumonia.